Fokal Başlangıçlı Epilepside Lakozamidin Ek Tedavideki Yeri

Bek, Semai; karadaş, ömer; Eroğlu, Erdal; Gökçil, Zeki; Koc, Guray

Fokal Başlangıçlı Epilepside Lakozamidin Ek Tedavideki Yeri

Güray KOÇ, (GATA Nöroloji Anabilim Dalı, Ankara, Türkiye)

VEDAT SEMAİ BEK, (Başkent Üniversitesi Tıp Fakültesi, Adana Eğitim ve Araştırma Merkezi, Nöroloji Kliniği, Adana)

Ömer KARADAŞ, (Gülhane Askeri Tıp Fakültesi, Nöroloji Anabilim Dalı, Ankara, Türkiye)

Erdal EROĞLU, (TOBB Ekonomi ve Teknoloji Üniversitesi Tıp Fakültesi, Nöroloji Anabilim Dalı, Ankara, Türkiye)

Zeki GÖKÇİL (Doğu Akdeniz Üniversitesi Sağlık Bilimleri Fakültesi, Fizyoterapi ve Rehabilitasyon Bölümü, Nöroloji Anabilim Dalı, KKTC)

Epilepsi

19 0

Yıl: 2017 Cilt: 23 Sayı: 3 Sayfa Aralığı: 103 - 108 Metin Dili: Türkçe İndeks Tarihi: 05-11-2018

Fokal Başlangıçlı Epilepside Lakozamidin Ek Tedavideki Yeri

Öz:

Amaç: İki veya daha fazla antiepileptik ilaç (AEİ) kullanan ve nöbetleri durmayan fokal başlangıçlı epilepsi hastalarında lakozamidin 200–300– 400 mg/gün dozlarda ek tedavi olarak kullanılmasının etkinliği ve güvenilirliğini geriye dönük olarak incelenmesi amaçlandı.Gereç ve Yöntem: Nöbetleri durmayan ve ek tedavi olarak en az altı ay boyunca lakozamid kullanan fokal başlangıçlı nöbetleri olan hastaların tıbbi kayıtları geriye dönük olarak incelendi. Demografik veriler, lakozamid dozu, birlikte kullandığı AEİ tedavisi ve birinci ve altıncı aylardaki nöbet aktivitesi incelendi.Bulgular: Toplam 83 hasta değerlendirildi. Nöbet sıklığındaki ortalama azalma birinci ayda %38.88, altıncı ayda %33.22 ve tedaviye %50 yanıt oranı birinci ayda %53, altıncı ayda %47 olarak bulundu. Lakozamid ile birlikte kullanılan ve sodyum kanalı üzerinden etki eden AEİ oranı %97.6 olarak bulundu. Doza bağımlı yan etkiler sersemlik, bulantı, diplopi, gastrointestinal yan etkiler, baş ağrısı, kaşıntı ve görme bulanıklığı olarak bulundu. İlaç yan etkisi tespit edilen hastaların hepsinin lakozamid ile birlikte sodyum kanalı üzerinden etki eden AEİ kullandığı tespit edildi.Sonuç: Kontrol altına alınamayan fokal başlangıçlı nöbetleri olan hastalarda ek lakozamid tedavisi nöbet sıklığını azaltmaktadır.

Anahtar Kelime:

Konular: Hematoloji

The Role of Add-On Lacosamide Therapy in the Treatment of Focal Onset Epilepsy Dr. Güray KOÇ

Öz:

Objectives: The aim of this study was to retrospectively evaluate the efficacy and safety of lacosamide (200-300-400 mg/day) as adjunct treatment in patients with uncontrolled focal-onset seizures taking 2 or more antiepileptic drugs (AED). Methods: A retrospective review of the medical records of patients with uncontrolled focal epilepsy who received lacosamide as add-on therapy for at least 6 months was performed. Data collected and analyzed included demographic information, lacosamide dosing, concomi-tant AED therapy, and seizure activity in first and sixth months. Results: A total of 83 patients were evaluated. The mean percent reduction in seizure frequency per month was 38.98% in the first month and 33.22% in the sixth month. In all, 53% of the patients had a decrease in seizures of 50% or more in the first month, and 47% saw a similar decrease in the sixth month . The percentage of those taking a sodium channel blocking AED in addition to lacosamide was 97.6%. Dose-related adverse events reported included dizziness, nausea, diplopia, gastroenterological side effects, headache, itchy skin, and blurred vi-sion. It was determined that all of the patients with drug-related side effects were taking a sodium channel blocking AED concomitantly with lacosamide. Conclusion: Adjuvant treatment with lacosamide reduced seizure frequency for patients with uncontrolled focal-onset seizures.

Anahtar Kelime:

Konular: Hematoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

23. Wechsler RT, Li G, French J, O’Brien TJ, D’Cruz O, Williams P, et al; ALEX-MT Study Group. Conversion to lacosamide mono-therapy in the treatment of focal epilepsy: results from a his-torical-controlled, multicenter, double-blind study. Epilepsia 2014;55(7):1088–98.
22. Giráldez BG, Toledano R, García-Morales I, Gil-Nagel A, López-González FJ, Tortosa D, et al. Long-term efficacy and safety of lacosamide monotherapy in the treatment of partial-onset sei-zures: A multicenter evaluation. Seizure 2015;29:119–22.
21. Genç F, Uçan Tokuç FE, Akça G, Aydemir Y, Kutlu G, Erdal A, et al. The Effectivety, Safety and Tolerability Profile of Lacosamide Therapy in Refractory Epilepsy: Premarketing Experience. Epi-lepsi 2014;20(3):121–5.
20. Schiller Y, Najjar Y. Quantifying the response to antiepi-leptic drugs: effect of past treatment history. Neurology 2008;70(1):54–65.
19. Sander JW. The use of antiepileptic drugs--principles and prac-tice. Epilepsia 2004;45 Suppl 6:28–34.
18. Steinhoff BJ, Eckhardt K, Doty P, De Backer M, Brunnert M, Schulze-Bonhage A. A long-term noninterventional safety study of adjunctive lacosamide therapy in patients with epi-lepsy and uncontrolled partial-onset seizures. Epilepsy Behav 2016;58:35–43.
17. Husain A, Chung S, Faught E, Isojarvi J, McShea C, Doty P. Long-term safety and efficacy in patients with uncontrolled partial-onset seizures treated with adjunctive lacosamide: results from a Phase III open-label extension trial. Epilepsia 2012;53(3):521– 8.
16. Ben-Menachem E, Biton V, Jatuzis D, Abou-Khalil B, Doty P, Rudd GD. Efficacy and safety of oral lacosamide as adjunc-tive therapy in adults with partial-onset seizures. Epilepsia 2007;48(7):1308–17.
15. Halász P, Kälviäinen R, Mazurkiewicz-Beldzińska M, Rosenow F, Doty P, Hebert D, et al; SP755 Study Group. Adjunctive lacos-amide for partial-onset seizures: Efficacy and safety results from a randomized controlled trial. Epilepsia 2009;50(3):443– 53.
14. Chung S, Sperling MR, Biton V, Krauss G, Hebert D, Rudd GD, et al; SP754 Study Group. Lacosamide as adjunctive therapy for partial-onset seizures: a randomized controlled trial. Epilepsia 2010;51(6):958–67.
13. Kinirons P, McCarthy M, Doherty CP, Delanty N. Predicting drug-resistant patients who respond to add-on therapy with leveti-racetam. Seizure 2006;15(6):387–92.
12. Sawh SC, Newman JJ, Deshpande S, Jones PM. Lacosamide adjunctive therapy for partial-onset seizures: a meta-analysis. PeerJ 2013;1:e114.
11. Beyreuther BK, Freitag J, Heers C, Krebsfänger N, Scharfenecker U, Stöhr T. Lacosamide: a review of preclinical properties. CNS Drug Rev 2007;13(1):21–42.
10. Chung SS. New treatment option for partial-onset seizures: efficacy and safety of lacosamide. Ther Adv Neurol Disord 2010;3(2):77–83.
9. Bek S, Kaşikçi T, Koç G, Genç G, Demirkaya S, Gökçil Z, et al. Cerebral vasomotor reactivity in epilepsy patients. J Neurol 2010;257(5):833–8.
8. French JA, Kanner AM, Bautista J, Abou-Khalil B, Browne T, Harden CL, et al. Efficacy and tolerability of the new antiepi-leptic drugs II: treatment of refractory epilepsy: report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology 2004;62(8):1261–73.
7. Guevara J, Carmona G, Ortega MP, Iglesias AA. Preliminary study on the efficacy and tolerability of newer anticonvul-sants in a population of epileptic patients. Med Princ Pract 2005;14(1):31–4.
6. Perucca E, French J, Bialer M. Development of new antiepilep-tic drugs: challenges, incentives, and recent advances. Lancet Neurol 2007;6(9):793–804.
5. Chung S, Wang N, Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure 2007;16(4):296–304.
4. Brodie MJ, Kwan P. Staged approach to epilepsy management. Neurology 2002;58(8 Suppl 5):S2–8.
3. Kelemen A, Halász P. Lacosamide for the prevention of partial onset seizures in epileptic adults. Neuropsychiatr Dis Treat 2010;6:465–71.
2. Loiseau P. Intractable epilepsy: Prognostic evaluation. In: Schmidt D, Morselli PL, editors. Intractable Epilepsy: Experi- mental and Clinical Aspects. New York: Raven Press; 1986.
1. From the Centers for Disease Control and Prevention. Preva-lence of self-reported epilepsy-United States, 1986-1990. JAMA 1994;272(24):1893.

APA	Koc G, Bek S, karadaş ö, Eroğlu E, Gökçil Z (2017). Fokal Başlangıçlı Epilepside Lakozamidin Ek Tedavideki Yeri. , 103 - 108.
Chicago	Koc Guray,Bek Semai,karadaş ömer,Eroğlu Erdal,Gökçil Zeki Fokal Başlangıçlı Epilepside Lakozamidin Ek Tedavideki Yeri. (2017): 103 - 108.
MLA	Koc Guray,Bek Semai,karadaş ömer,Eroğlu Erdal,Gökçil Zeki Fokal Başlangıçlı Epilepside Lakozamidin Ek Tedavideki Yeri. , 2017, ss.103 - 108.
AMA	Koc G,Bek S,karadaş ö,Eroğlu E,Gökçil Z Fokal Başlangıçlı Epilepside Lakozamidin Ek Tedavideki Yeri. . 2017; 103 - 108.
Vancouver	Koc G,Bek S,karadaş ö,Eroğlu E,Gökçil Z Fokal Başlangıçlı Epilepside Lakozamidin Ek Tedavideki Yeri. . 2017; 103 - 108.
IEEE	Koc G,Bek S,karadaş ö,Eroğlu E,Gökçil Z "Fokal Başlangıçlı Epilepside Lakozamidin Ek Tedavideki Yeri." , ss.103 - 108, 2017.
ISNAD	Koc, Guray vd. "Fokal Başlangıçlı Epilepside Lakozamidin Ek Tedavideki Yeri". (2017), 103-108.

APA	Koc G, Bek S, karadaş ö, Eroğlu E, Gökçil Z (2017). Fokal Başlangıçlı Epilepside Lakozamidin Ek Tedavideki Yeri. Epilepsi, 23(3), 103 - 108.
Chicago	Koc Guray,Bek Semai,karadaş ömer,Eroğlu Erdal,Gökçil Zeki Fokal Başlangıçlı Epilepside Lakozamidin Ek Tedavideki Yeri. Epilepsi 23, no.3 (2017): 103 - 108.
MLA	Koc Guray,Bek Semai,karadaş ömer,Eroğlu Erdal,Gökçil Zeki Fokal Başlangıçlı Epilepside Lakozamidin Ek Tedavideki Yeri. Epilepsi, vol.23, no.3, 2017, ss.103 - 108.
AMA	Koc G,Bek S,karadaş ö,Eroğlu E,Gökçil Z Fokal Başlangıçlı Epilepside Lakozamidin Ek Tedavideki Yeri. Epilepsi. 2017; 23(3): 103 - 108.
Vancouver	Koc G,Bek S,karadaş ö,Eroğlu E,Gökçil Z Fokal Başlangıçlı Epilepside Lakozamidin Ek Tedavideki Yeri. Epilepsi. 2017; 23(3): 103 - 108.
IEEE	Koc G,Bek S,karadaş ö,Eroğlu E,Gökçil Z "Fokal Başlangıçlı Epilepside Lakozamidin Ek Tedavideki Yeri." Epilepsi, 23, ss.103 - 108, 2017.
ISNAD	Koc, Guray vd. "Fokal Başlangıçlı Epilepside Lakozamidin Ek Tedavideki Yeri". Epilepsi 23/3 (2017), 103-108.